What happened
Shares of Jazz Pharmaceuticals PLC, an Irish-based biopharmaceutical company primarily focused on the development of therapies to treat sleep disorders, fell 10% in October, based on data from S&P Global Market Intelligence.
Although it was a pretty quiet month in terms of press releases for Jazz, the culprit appears to be pricing concerns for its lead drug, Xyrem.
So what
One campaign issue that’s gained a lot of press since September 2015 is prescription-drug reform.
